Of them, 14 studies were further excluded; four were preclinical studies, two did not include patients with glioma, four did not report the outcome of OS, three did not measure tumor expression of CD44, and one was a repeated report of an included study. This evidence concerns the gene CD44 and central nervous system cancer.